Skye Bioscience Inc (SKYE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.86+4.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SKYE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SKYE — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 18, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($497,307), and therefore, the Company was…
Why it matters: The notice of delisting could impact investor confidence. Staying listed is crucial for capital access.
Worry ifThe company confirms it follows Nasdaq listing rules.
Less concerning ifThe company risks delisting or does not meet Nasdaq rules.
Why it matters: The delisting notice may hurt Skye's ability to raise money and run well.
Worry ifSkye gets confirmation that it fixed the delisting issue with Nasdaq.
Less concerning ifSkye fails to meet Nasdaq's requirements and faces delisting.
Why it matters: Partnerships can improve Skye's drug delivery and market reach.
Supportive ifLook for news on a new partnership that helps nimacimab delivery.
Worry ifNo new partnerships mean slow growth in strategy.
Why it matters: Progress in clinical trials is key for Skye's growth and future revenue.
Supportive ifA trial phase is successful or there are good interim results for nimacimab.
Worry ifNews of trial delays or negative results from ongoing studies.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$318 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $904 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,558 loss on $10,000 · 95.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Keeping spending in check is important as losses go on. It affects funding.
Watch forManagement says cost-cutting measures are working. Cash burn is stable.
Also watch forManagement announces higher cash burn or failure to meet spending control goals.
Why it matters: Closing the acquisition will create Fibrx Therapeutics and could enhance growth prospects.
Supportive ifThe acquisition will close in Q4 2026 as planned. All regulatory approvals are in place.
Worry ifThe acquisition fails to close by the end of Q4 2026 due to unmet conditions.
Why it matters: Starting the Phase 2 study is crucial for advancing the lead asset in treating Crohn's disease.
Supportive ifThe Phase 2 clinical study for RXC008 begins as scheduled with patient enrollment.
Worry ifThe Phase 2 study is delayed or does not start as planned.